REGULATION OF PULMONARY VASCULAR TONE

肺血管张力的调节

• 批准号: 3074419
• 负责人: JOHN R MICHAEL
• 金额: $ 5.62万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-09-01 至 1994-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3074419
• 关键词: angiotensin II; biological signal transduction; calcium metabolism; cardiovascular disorder chemotherapy; cardiovascular pharmacology; cyclic AMP; cyclic GMP; deficient growth media; immunocytochemistry; laboratory rabbit; norepinephrine; nucleic acid probes; potassium chloride; protein kinase C; pulmonary artery; pulmonary circulation; pulmonary hypertension; serotonin; thromboxanes; tissue /cell culture; vascular endothelium; vascular smooth muscle; vasoactive agent; vasoconstrictors; vasodilators; vasomotion; vasopressins

The candidate's long-term career objective is to understand the mechanisms that regulate pulmonary vascular tone in the expectation that this will eventually improve therapy for patients with pulmonary hypertension. His research has evolved from studies in patients and awake animals to the study of isolated vessels and cells. This change has been driven by the conviction that Current therapy for pulmonary hypertension is ineffective because of inadequate understanding of the basic mechanisms that regulate Pulmonary vascular tone. The scientific focus of this proposal is to understand vasoconstrictor and vasodilator mediated signal transduction in pulmonary vascular tissue. The investigator's research group is moving to the University of Utah to take advantage of colla ration with experts in cell biology (Dr. John R. Hoidal), intracellular Ca++ (Dr. William H. Barry), and signal transduction (Dr. Stephen M. Prescott and Dr. Guy A. Zimmerman). The proposed experiments combine biochemical and physiological measurements. The first specific aim will define the effects of pulmonary vasoconstrictors on 45 Ca++ entry in pulmonary vessels and the release of intracellular Ca++ in pulmonary artery endothelial and smooth muscle cells. The second specific aim will test the hypothesis that vasoconstrictors activate the phosphatidylinositol cycle and that these products contribute to vasoconstriction by increasing intracellular Ca +4 and activating protein kinase C. This specific aim will determine whether vasoconstrictors stimulate the production of 1,2 diacylglycerols and hydrolysis of phosphoinositides in pulmonary artery endothelial and smooth muscle cells. The importance of these products will be tested by studying the effect of inhibitors of phospholipase C and protein kinase C on agonist-induced pulmonary vasoconstriction. The third specific alm will determine the ability of cyclic AMP or cyclic GMP to prevent agonist-induced vasoconstriction. This specific aim will also determine the effects of cyclic AMP and cyclic GMP on agonist-induced Ca++ entry, intracellular Ca 4+ release, and the formation of 1,2 diacylglycerols or the hydrolysis of phosphoinositides. The fourth specific alm will investigate the mechanisms by which pulmonary vasoconstrictors inhibit the action of vasodilators. Possible mechanisms for this functional antagonism will be studied including the hypothesis that activation of protein kinase C inhibits the increase in cyclic AMP caused by isoproterenol by stimulating a pertussis toxin sensitive guanine nucleotide regulatory protein (Gi or Go). The proposed research will lead to a better understanding of the mechanisms by which vasoconstrictors and vasodilators act alone and in concert to control pulmonary vascular tone.

候选人的长期职业目标是了解这些机制